Insmed Inc (INSM) Soars 30% on Impressive Study
From Yahoo Finance: 2025-06-12 18:32:00
Insmed Inc. (INSM) saw a 30% surge in stock price after positive phase 2 trial results for their PAH treatment, reaching $90.93 per share. The company plans to engage with the FDA for a phase 3 trial design. INSM aims to start a Phase 3 trial for PH-ILD patients this year.
The phase 2 trial for Insmed Inc’s treprostinil palmitil inhalation powder (TPIP) showed success in reducing blood pressure in the lungs and improving exercise capacity. The company plans to initiate phase 3 trials for pulmonary hypertension patients, with high hopes for the treatment’s efficacy.
Insmed Inc. leads the list of top-performing companies following the positive phase 2 trial results for TPIP. While INSM shows promise as an investment, some believe other AI stocks offer higher returns with less risk. For more on AI stock recommendations, check out Insider Monkey’s reports.